Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 39, 2009 - Issue 10
Submit an article Journal homepage
200
Views
29
CrossRef citations to date
0
Altmetric
Research Article

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects

Z. LiPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
G. WangPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
L.-S. WangPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
W. ZhangPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
Z.-R. TanPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
L. FanPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
B.-L. ChenPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
Q. LiPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
J. LiuPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
J.-H. TuPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
D.-L. HuPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
,
Z.-Q. LiuPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. China
&
H.-H. ZhouPharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, P. R. ChinaCorrespondence[email protected]
 show all
Pages 788-793 | Received 27 Apr 2009, Accepted 22 Jun 2009, Published online: 15 Jul 2009

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Shogo Matsumoto, Shotaro Uehara, Hidetaka Kamimura, Naoki Cho, Hiroshi Ikeda, Satoshi Maeda, Kensuke Kagiyama, Atsunori Miyata, Hiroshi Suemizu & Kazumasa Fukasawa. (2022) Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets. Xenobiotica 52:6, pages 613-624.
Read now
Dongxu Wang, Da-Peng Dai, Hualan Wu, Jia Chong, You Lü, Ruoyun Yin, Xinlong Zhao, Anxu Zhao, Jiefu Yang & Hao Chen. (2020) Effects of Rare CYP2C9 Alleles on Stable Warfarin Doses in Chinese Han Patients with Atrial Fibrillation. Pharmacogenomics 21:14, pages 1021-1031.
Read now
Baiping Dong, Suowei Yuan, Jinsheng Hu & Yanzhen Yan. (2018) Effects of Ginkgo leaf tablets on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. Pharmaceutical Biology 56:1, pages 333-336.
Read now
Michel Burnier & Grégoire Wuerzner. (2011) Pharmacokinetic evaluation of losartan. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 643-649.
Read now

Articles from other publishers (25)

Dongxu Wang, Hualan Wu, Qing Zhang, Xiaoyue Zhou, Yang An, Anxu Zhao, Jia Chong, Shuanghu Wang, Fang Wang, Jiefu Yang, Dapeng Dai & Hao Chen. (2023) Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants. European Journal of Clinical Pharmacology 79:10, pages 1315-1320.
Crossref
Abdul Ahad, Mohammad Raish, Ibrahim Abdelsalam Abdelrahman, Yousef A. Bin Jardan, Mohd Aftab Alam, Abdullah M. Al-Mohizea & Fahad I. Al-Jenoobi. (2022) Changes in Pharmacokinetics and Pharmacodynamics of Losartan in Experimental Diseased Rats Treated with Curcuma longa and Lepidium sativum. Pharmaceuticals 16:1, pages 33.
Crossref
Dongxu Wang, Hualan Wu, Min Dong, Qing Zhang, Anxu Zhao, Xinlong Zhao, Jia Chong, Minghui Du, Yan Wang, Haifeng Shi, Shuanghu Wang, Fang Wang, Jianping Cai, Jiefu Yang, Dapeng Dai & Hao Chen. (2022) Clinical significance of the series of CYP2C9*non3 variants, an unignorable predictor of warfarin sensitivity in Chinese population. Frontiers in Cardiovascular Medicine 9.
Crossref
Cangsang Song, Xingde Li, Panpan Mao, Wenbing Song, Lu Liu & Yang Zhang. (2022) Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy. European Journal of Hospital Pharmacy 29:4, pages 198-201.
Crossref
G. I. Gorodetskaya, N. D. Bunyatyan, E. S. Mel’nikov, T. A. Rodina, S. A. Belkov & L. M. Krasnykh. (2022) A Method for Assay of Losartan, Its Active Metabolite E-3174, and Glibenclamide in Human Serum and Urine by HPLC-MS/MS. Pharmaceutical Chemistry Journal 56:1, pages 118-125.
Crossref
Yoon-A Park, Yu-bin Song, Jeong Yee, Ha-Young Yoon & Hye-Sun Gwak. (2021) Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine 11:7, pages 617.
Crossref
Abdul Ahad, Mohammad Raish, Yousef A. Bin Jardan, Mohd Aftab Alam, Abdullah M. Al-Mohizea & Fahad I. Al-Jenoobi. (2020) Potential pharmacodynamic and pharmacokinetic interactions of Nigella Sativa and Trigonella Foenum-graecum with losartan in L-NAME induced hypertensive rats. Saudi Journal of Biological Sciences 27:10, pages 2544-2550.
Crossref
Se-Hyung Kim, Do-Hoon Kim, Ji-Yeong Byeon, Young-Hoon Kim, Dong-Hyun Kim, Hye-Jin Lim, Choong-Min Lee, Sang Sup Whang, Chang-Ik Choi, Jung-Woo Bae, Yun Jeong Lee, Choon-Gon Jang & Seok-Yong Lee. (2016) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Archives of Pharmacal Research 40:3, pages 382-390.
Crossref
Felicia Stefania Falvella, Susan Marelli, Stefania Cheli, Stefano Montanelli, Federico Viecca, Lucia Salvi, Alfio Ferrara, Emilio Clementi, Giuliana Trifirò & Alessandro Pini. (2016) Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?. Drug Metabolism and Personalized Therapy 31:3, pages 157-163.
Crossref
Hyun-Jee Lee, Young-Hoon Kim, Se-Hyung Kim, Choong-Min Lee, Ae-Yun Yang, Choon-Gon Jang, Seok-Yong Lee, Jung-Woo Bae & Chang-Ik Choi. (2016) Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Archives of Pharmacal Research 39:7, pages 1013-1019.
Crossref
Yun-Jeong Lee, Ji-Yeong Byeon, Young-Hoon Kim, Se-Hyung Kim, Chang-Ik Choi, Jung-Woo Bae, Uy-Dong Sohn, Choon-Gon Jang, Jeongmi Lee & Seok-Yong Lee. (2015) Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Archives of Pharmacal Research 38:6, pages 1232-1237.
Crossref
Guo-Xin Hu, Pei-Pei Pan, Zeng-Shou Wang, Li-Ping Yang, Da-Peng Dai, Shuang-Hu Wang, Guang-Hui Zhu, Xiang-Jun Qiu, Tao Xu, Jun Luo, Qing-Quan Lian, Ren-Shan Ge & Jian-Ping Cai. (2015) In Vitro and In Vivo Characterization of 13 CYP2C9 Allelic Variants Found in Chinese Han Population. Drug Metabolism and Disposition 43:4, pages 561-569.
Crossref
Da‐Peng Dai, Shuang‐Hu Wang, Pei‐Wu Geng, Guo‐Xin Hu & Jian‐Ping Cai. (2013) In Vitro Assessment of 36 CYP 2 C 9 Allelic Isoforms Found in the C hinese Population on the Metabolism of Glimepiride . Basic & Clinical Pharmacology & Toxicology 114:4, pages 305-310.
Crossref
D-P Dai, R-A Xu, L-M Hu, S-H Wang, P-W Geng, J-F Yang, L-P Yang, J-C Qian, Z-S Wang, G-H Zhu, X-H Zhang, R-S Ge, G-X Hu & J-P Cai. (2013) CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. The Pharmacogenomics Journal 14:1, pages 85-92.
Crossref
Panida Lertkiatmongkol, Anunchai Assawamakin, George White, Gaurav Chopra, Pornpimol Rongnoparut, Ram Samudrala & Sissades Tongsima. (2013) Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin. PLoS ONE 8:9, pages e74053.
Crossref
Y Tomita, K Maeda & Y Sugiyama. (2012) Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism. Clinical Pharmacology & Therapeutics 94:1, pages 37-51.
Crossref
Martin C. Michel, Carolyn Foster, Hans R. Brunner & Lisheng Liu. (2013) A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews 65:2, pages 809-848.
Crossref
Dayong Si, Juan Wang, Yifan Zhang, Dafang Zhong & Hui Zhou. (2012) Distribution of CYP2C9*13 allele in the Chinese Han and the long‐range haplotype containing CYP2C9*13 and CYP2C19*2 . Biopharmaceutics & Drug Disposition 33:6, pages 342-345.
Crossref
Ying Guo, Yao Chen, Zhi-rong Tan, Curtis D. Klaassen & Hong-hao Zhou. (2011) Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology 68:2, pages 213-217.
Crossref
Chang-Ik Choi, Mi-Jeong Kim, Eun-Kyung Chung, Hye-In Lee, Choon-Gon Jang, Jung-Woo Bae & Seok-Yong Lee. (2011) CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European Journal of Clinical Pharmacology 68:2, pages 149-154.
Crossref
Chang-Ik Choi, Mi-Jeong Kim, Choon-Gon Jang, Young-Seo Park, Jung-Woo Bae & Seok-Yong Lee. (2011) Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam. Basic & Clinical Pharmacology & Toxicology 109:6, pages 476-480.
Crossref
Min-Jung Kwon, Young-Keun On, Wooseong Huh, Jae-Wook Ko, Duk-Kyung Kim, June Soo Kim & Soo-Youn Lee. (2011) Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype. Clinica Chimica Acta 412:23-24, pages 2343-2345.
Crossref
Jung-woo Bae, Chang-ik Choi, Mi-jeong Kim, Da-hee Oh, Seul-ki Keum, Jung-in Park, Bo-hye Kim, Hye-kyoung Bang, Sung-gon Oh, Byung-sung Kang, Hyun-joo Park, Hae-deun Kim, Ji-hey Ha, Hee-jung Shin, Young-hoon Kim, Han-sung Na, Myeon-woo Chung, Choon-gon Jang & Seok-yong Lee. (2011) Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics. Acta Pharmacologica Sinica 32:10, pages 1303-1308.
Crossref
Jung‐Woo Bae, Chang‐Ik Choi, Choon‐Gon Jang & Seok‐Yong Lee. (2011) Effects of CYP2C9 * 1/ * 13 on the pharmacokinetics and pharmacodynamics of meloxicam . British Journal of Clinical Pharmacology 71:4, pages 550-555.
Crossref
Jing Zi, Duan Liu, Pingping Ma, He Huang, Juanli Zhu, Dongqing Wei, Jin Yang & Chao Chen. (2010) Effects of CYP2C9*3 and CYP2C9* 13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions. Drug Metabolism and Pharmacokinetics 25:4, pages 343-350.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.